KYL

EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM), which inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM), prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. It shows neuroprotective effect.

Online Inquiry

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	R0975
CAS	676657-00-4
Background	The KYL peptide, which appeared to bind best to EphA4, has since been used in organotypic cultures to implicate EphA4 in chicken neural crest cell migration and mouse hippocampal axon arborization as well as in adhesion assays to demonstrate the importance of the receptor in integrin-dependent adhesion of human T-cells. >> Read More
M.F/Formula	C74H108N14O17
M.W/Mr.	1465.75
Sequence	KYLPYWPVLSSL
Labeling Target	EphA4 receptor tyrosine kinase
Activity	Inhibitor

CAT#	Product Name	M.W	Molecular Formula	Inquiry
R1025	Z-Leu-Leu-Glu-AMC	664.76	C₃₅H₄₄N₄O₉	Inquiry
R1026	Z-Leu-Arg-Gly-Gly-AMC	692.77	C₃₄H₄₄N₈O₈	Inquiry
R1032	Chlorotoxin	599.64	C29H37N5O9S1	Inquiry
R1034	Ac-Trp-Leu-Ala-AMC	718.7	C35H38N6O11	Inquiry
R1054	Norleual	774.95	C41H58N8O7	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Storage	-20°C
InChI	InChI=1S/C74H108N14O17/c1-40(2)31-52(64(94)84-59(39-90)68(98)85-58(38-89)67(97)83-57(74(104)105)33-42(5)6)80-71(101)62(43(7)8)86-70(100)61-19-14-30-88(61)73(103)56(36-46-37-77-51-17-10-9-15-49(46)51)82-66(96)54(35-45-22-26-48(92)27-23-45)79-69(99)60-18-13-29-87(60)72(102)55(32-41(3)4)81-65(95)53(34-44-20-24-47(91)25-21-44)78-63(93)50(76)16-11-12-28-75/h9-10,15,17,20-27,37,40-43,50,52-62,77,89-92H,11-14,16,18-19,28-36,38-39,75-76H2,1-8H3,(H,78,93)(H,79,99)(H,80,101)(H,81,95)(H,82,96)(H,83,97)(H,84,94)(H,85,98)(H,86,100)(H,104,105)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m0/s1
InChI Key	FZNPYIAZMDBRLC-RKNDTPCJSA-N
Isomeric SMILES	CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CCCCN)N
References	KYL was also shown to prevent growth cone collapse in chicken retinal explants and dissociated cultures of rat cortical neurons, promote nerve regeneration and functional recovery in a rat model of spinal cord injury, and inhibit the adhesion of human T-cells to endothelial cells. Thus, KYL can target human, mouse, rat and chicken EphA4 and may be useful for promoting nerve regeneration after injury and modulating immune responses. Distinctive Binding of Three Antagonistic Peptides to the Ephrin-Binding Pocket of the EphA4 Receptor STI and KYL inhibitors prevented AβO-induced dendritic spine loss. Although the absence of EphA4 did not completely rescue the dendritic spine loss, EphA4-knockout neurons show a significant decrease in AβO-induced dendritic spine loss. Furthermore, protection was observed in mature neurons (with established synapses) transfected with either c-Abl shRNA or EphA4 shRNA. EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-β oligomers